



Plaque psoriasis?

Consider our clinical study

Beyond the physical discomfort, psoriasis can have a real impact on daily life for many people.¹ Many patients with moderate-to-severe psoriasis manage the disease with topical (on the skin) drugs. However, for many, this form of treatment is not enough.²⁻⁴ We at Bristol-Meyers Squibb are committed to helping patients overcome autoimmune diseases like psoriasis. That is why we are conducting this study – to see whether we are able to develop a potential new treatment option that is more effective and easier to use consistently than existing treatments.

To be eligible for this study, you must (among other things):

- © Be at least 18 years old
- © Have moderate-to-severe plaque psoriasis (for at least 6 months)

Please take a flyer to learn more about this study.

Why are we conducting this research?

We are conducting this study to look at whether a study drug is safe and effective in treating individuals with moderate-to-severe plaque psoriasis.

What will happen if I join?

If you would like to join, we will ask you to sign an informed consent form to understand key information about the study, including purpose, procedures, risks and benefits. Then, a study doctor will examine you and talk through your medical history to determine if you are eligible to participate. If you are, you will need to visit the study clinic for regular assessments. The study drug, study visits and any related medical tests will be provided at no cost to you or your insurance company. You may be responsible for other costs (for example, tests you would receive as the usual care for your disease), some of which may be covered by your insurance.

If you think you or someone you know may be interested in taking part or you would like more information, please contact the study team using the details below.

Houston Center for Clinical Research
3519 Town Center Blvd. Suite B
Sugar Land, TX 77479
Ph: 832-929-6221

1. World Health Organization. Global report on psoriasis. 2016. 2. Nestle FO, Kaplan DH, Barker J. Mechanisms of Disease: Psoriasis. *N Engl J Med* 2009;361:496-509. 3. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. *Ann Rheum Dis* 2005;64(Suppl II):ii18-ii23. 4. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebowitz MG. Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Subjects with Psoriasis and Psoriatic Arthritis in the United States. Findings from the National Psoriasis Foundation Surveys, 2003- 2011. *JAMA Dermatol* 2013;149(10):1180-1185.